Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sudarsan Kollimuttathuliam, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 4576.

https://doi.org/10.1182/blood-2019-132052

Published: 2019

Journal Articles

Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Jordan Nunnelee, BA, Qiuhong Zhao, MS, Don M. Benson, Jr., MD PhD, Ashley E. Rosko, MD, Maria Chaudhry, MD, Naresh Bumma, MD, Abdullah Mohammad Khan, MBBS,MSc, Srinivas Devarakonda, MD, Yvonne A. Efebera, MD MPH, Nidhi Sharma, PhD

Blood (2019) 134 (Supplement_1): 4573.

https://doi.org/10.1182/blood-2019-121845

Published: 2019

Journal Articles

Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data of a Prospective Study in a Single Institution

Iván Murrieta-Álvarez, MD, David P. Steensma, MD, Juan Carlos Olivares-Gazca, MD, Jesús Mauricio Olivares-Gazca, MD, Andrés A. León-Peña, MD, Yahveth Cantero-Fortiz, MD, Yarely Itzayana García-Navarrete, MD, Antonio Cruz-Mora, MD, Alejandro Ruiz-Argüelles, MD, Guillermo J. Ruiz-Delgado, MD FACP, Guillermo J. Ruiz-Arguelles, FRCP, MACP

Blood (2019) 134 (Supplement_1): 5707.

https://doi.org/10.1182/blood-2019-128972

Published: 2019

Journal Articles

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Ljupco Veskovski, MD, Per-Ola Andersson, MD PhD, Ingemar Turesson, MD PhD, Daniel Malmodin, PhD, Anders Pedersen, PhD, Ulf-Henrik Mellqvist, MD PhD

Blood (2019) 134 (Supplement_1): 1771.

https://doi.org/10.1182/blood-2019-121961

Published: 2019

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy

Praful Ravi, MB BChir, Shaji Kumar, MD, Wilson I Gonsalves, MD, Francis K Buadi, MD, Martha Q. Lacy, MD, Ronald S. Go, MD, Angela Dispenzieri, MD, Prashant Kapoor, MD, John A Lust, MD PhD, David Dingli, MD PhD FRCP, Yi Lin, MD PhD, Stephen J. Russell, MD PhD, Nelson Leung, MD, Morie A. Gertz, MD, Robert A. Kyle, MD, Leif Bergsagel, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 3251.

https://doi.org/10.1182/blood.V128.22.3251.3251

Published: 2016

Journal Articles

Abnormal Heavy/Light Chain Ratio after Treatment Is a Robust Predictor of Shorter Survival in Patients with IgA Myeloma

Yoshiaki Abe, MD, Yasuhito Suehara, MD, Hiroyuki Takamatsu, MD PhD, Yoshiaki Usui, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kelly Endean, PhD, Kosei Matsue, MD PhD

Blood (2016) 128 (22): 3254.

https://doi.org/10.1182/blood.V128.22.3254.3254

Published: 2016

Journal Articles

Defining Fundamental B Cell-Subset Dysfunction in Myeloma

Rao H Prabhala, PhD, Srikanth Talluri, PhD, Megan Stekla, BS, Andreea Negroiu, MD, Michael Buonopane, BS, Kevin LaBlanc, BS, Alex Heubeck, BS, Mariateresa Fulciniti, PhD, Kenneth Anderson, MD, Nikhil Munshi, MD

Blood (2016) 128 (22): 2085.

https://doi.org/10.1182/blood.V128.22.2085.2085

Published: 2016

Journal Articles

Multiple Myeloma (MM): Impact of Immunoglobulin Isotype on the Speed of Response

Helene Caillon, Michel Attal, Philippe Moreau, MD PhD, Thomas Dejoie

Blood (2015) 126 (23): 4191.

https://doi.org/10.1182/blood.V126.23.4191.4191

Published: 2015

Journal Articles

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience

Eli Muchtar, MD, Adi Zelig, Eyal Robenshtok, MD, Tzippy Shochat, MSc, Nino Oniashvili, PhD, Irina Amitai, MD, Pia Raanani, MD, Hila Magen, MD

Blood (2015) 126 (23): 5386.

https://doi.org/10.1182/blood.V126.23.5386.5386

Published: 2015

Journal Articles

Successful Stem Cell Mobilization with High-Dose Cytarabine Plus G-CSF after Lenalidomide Therapy for Multiple Myeloma - a Series of Four Cases

Jun Ishiko, MDPhD, Kazuaki Sato, MD, Ruri Kato, MD, Manabu Kawakami, MD PhD, Masashi Nakagawa, Yuzuru Kanakura

Blood (2014) 124 (21): 5831.

https://doi.org/10.1182/blood.V124.21.5831.5831

Published: 2014

Journal Articles

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

Lidia Usnarska-Zubkiewicz, Jakub Debski, MD, Aleksandra K. Butrym, MD, PhD, Wojciech Legiec, Marek Hus, MD, PhD, Anna Dmoszynska, Beata Stella-Holowiecka, MD, Jan M Zaucha, Marcin Rymko, MD, Tigran Torosian, MD, Grzegorz Charlinski, Ewa Lech-Maranda, Artur J. Jurczyszyn, MD, PhD, Halina Urbanska-Rys, Agnieszka Druzd-Sitek, PhD, Kazimierz Kuliczkowski

Blood (2013) 122 (21): 3236.

https://doi.org/10.1182/blood.V122.21.3236.3236

Published: 2013

Journal Articles

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Blood (2013) 122 (21): 1866.

https://doi.org/10.1182/blood.V122.21.1866.1866

Published: 2013

Journal Articles

Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011

Cecilie Blimark, MD, Erik Holmberg, PhD, Gunnar Juliusson, MD, PhD, Hareth Nahi, MD, PhD, Forsberg Karin, MD, PhD, Ingemar Turesson, MD, PhD, Lucia Ahlberg, MD., PhD., Ronald Svensson, MD, Olle Linder, MD, Kristina Carlsson, MD, PhD, Sigurdur Y Kristinsson, M.D., Ph.D.

Blood (2013) 122 (21): 1972.

https://doi.org/10.1182/blood.V122.21.1972.1972

Published: 2013

Journal Articles

Pseudo-Auer rods in a patient with newly diagnosed IgG myeloma

Stefani Parmentier, Joergen Radke

Blood (2012) 119 (3): 650.

https://doi.org/10.1182/blood-2010-12-326884

Published: 2012

Journal Articles

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma (MM) Patients: a Preliminary Report of Polish Myeloma Group

Lidia Usnarska-Zubkiewicz, MD, Jakub Debski, MD, Aleksandra Butrym, MD, Wojciech Legiec, MD, Anna Dmoszynska, Beata Stella-Holowiecka, MD, Jan Maciej Zaucha, MD, Marcin Rymko, MD, Tigran Torosian, MD, Kazimierz Kuliczkowski

Blood (2011) 118 (21): 5125.

https://doi.org/10.1182/blood.V118.21.5125.5125

Published: 2011

Journal Articles

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,

Efstathios Kastritis, Lia A Moulopoulos, Maria Gkotzamanidou, Dimitra Gika, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Meletios Athanasios Dimopoulos, MD

Blood (2011) 118 (21): 3926.

https://doi.org/10.1182/blood.V118.21.3926.3926

Published: 2011

Journal Articles

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.

Herve AvetLoiseau, MD, Jean-Luc Harousseau, Philippe Moreau, MD, Claire Mathiot, Thierry Facon, Michel Attal, MD, Arthur Bradwell, FRCP, FRCPath, Stephen Harding, PhD

Blood (2009) 114 (22): 1818.

https://doi.org/10.1182/blood.V114.22.1818.1818

Published: 2009

Journal Articles

Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.

Parameswaran N Hari, MD, A. John Barrett, MD, Smriti Shrestha, MS, MA, Gisela Tunes da Silva, PhD, Mei-Jie Zhang, PhD, Angela Dispenzieri, MD, Gustavo A. Milone, MD, Sagar Lonial, MD, Olle Ringden, MD

Blood (2009) 114 (22): 53.

https://doi.org/10.1182/blood.V114.22.53.53

Published: 2009

Journal Articles

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Martina Kleber, MD, Peter Haas, Bernd Koch, Manuela Burbeck, Monika Engelhardt

Blood (2009) 114 (22): 4945.

https://doi.org/10.1182/blood.V114.22.4945.4945

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience

Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data of a Prospective Study in a Single Institution

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy

Abnormal Heavy/Light Chain Ratio after Treatment Is a Robust Predictor of Shorter Survival in Patients with IgA Myeloma

Defining Fundamental B Cell-Subset Dysfunction in Myeloma

Multiple Myeloma (MM): Impact of Immunoglobulin Isotype on the Speed of Response

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience

Successful Stem Cell Mobilization with High-Dose Cytarabine Plus G-CSF after Lenalidomide Therapy for Multiple Myeloma - a Series of Four Cases

Efficacy Of Lenalidomide Treatment In Multiple Myeloma (MM) Patients – a Report of Polish Myeloma Group

Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?

Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011

Pseudo-Auer rods in a patient with newly diagnosed IgG myeloma

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma (MM) Patients: a Preliminary Report of Polish Myeloma Group

Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,

Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial.

Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.

Sensitive Detection of Renal Function in Multiple Myeloma (MM) Patients (pts) Via Estimated Glomerular Filtration Rate (eGFR) Unmasks Manifest Renal Function in Pts Receiving Lenalidomide and Suggests to Serve as An Additional Predictive Tool of Treatment Response.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only